2 completed, 1 recruiting. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Robert C. Martin: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone 1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone - Hepatocellular Carcinoma | Phase 2 | Recruiting | Robert C. Martin | 315 | 2024-07-24 | 2026-09-04 |
| Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo, Gem-Cis or Gem-Carbo - Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Robert C. Martin | 49 | 2012-07-01 | 2025-02-27 |
| LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma LC beads loaded with Doxorubicin - Stage IV Melanoma | Not applicable | Completed | Robert C. Martin | 20 | 2009-09-01 | 2018-10-25 |
Carcinoma, Hepatocellular (1) · Melanoma (1)
Injections (1) · N-dihydrogalactochitosan (1)
United States (3)
Robert CG Martin, MD, PhD (2) · Robert Martin, MD, PhD (1)